Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Leukemia" returned 7 results:

Intensified Methotrexate,Nelarabine & Augmented BFM Ther (AALL0434)
Principal Investigator(s): Birte Wistinghausen

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Principal Investigator(s): Luis M. Isola

AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC# 606869) in the Very High Risk Stratum
Principal Investigator(s): Birte Wistinghausen

AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Principal Investigator(s): Dr Birte Wistinghausen

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
Principal Investigator(s): Birte Wistinghausen

Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Principal Investigator(s): Birte Wistinghausen

AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
Principal Investigator(s): Birte Wistinghausen